The molecular basis of haemophilia A and B
- PMID: 8800501
- DOI: 10.1016/s0950-3536(96)80059-x
The molecular basis of haemophilia A and B
Abstract
Most families with haemophilia A or B carry gene defects of independent origin. Haemophilia B is mostly due to small changes in the factor IX gene affecting either its transcription, mRNA maturation, mRNA translation or the fine structure of factor IX. Only 2-3% of patients show gross deletions or rearrangements. The great variety of missense mutations reported to cause haemophilia B indicates that this multidomain protein is highly constrained. Less is known about the factor VIII gene as fully efficient mutation detection procedures only became available in 1991. This, however, led to the discovery that almost half the severe cases of haemophilia A or a fifth of all cases are due to frequently occurring inversions caused by homologous intra-chromosome (-chromatid) recombination between repeated sequences 9.5 kb long. Of the three repeats one is in intron 22 of the factor VIII gene and two are 400-500 kb more telomeric. They are 99.8% similar to each other. The spectrum of the other haemophilia A mutations is similar to that of haemophilia B. Since 1983 mounting evidence has shown that in both haemophilias the nature of the mutation is important in predisposing to the inhibitor complication.
Similar articles
-
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.Br J Haematol. 2013 Jan;160(2):153-70. doi: 10.1111/bjh.12091. Epub 2012 Nov 15. Br J Haematol. 2013. PMID: 23157203 No abstract available.
-
Key issues in inhibitor management in patients with haemophilia.Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s319-29. doi: 10.2450/2013.0246-12. Epub 2013 Dec 3. Blood Transfus. 2014. PMID: 24333092 Free PMC article. Review. No abstract available.
-
Inhibitors - cellular aspects and novel approaches for tolerance.Haemophilia. 2014 May;20 Suppl 4(0 4):80-6. doi: 10.1111/hae.12407. Haemophilia. 2014. PMID: 24762281 Free PMC article. Review.
-
Switching haemophilia products and inhibitor risk: a United States' perspective.Eur J Haematol. 2015 Apr;94(4):283. doi: 10.1111/ejh.12441. Eur J Haematol. 2015. PMID: 25800968 No abstract available.
-
Identification of mutations in the F8 and F9 gene in families with haemophilia using targeted high-throughput sequencing.Haemophilia. 2016 Sep;22(5):e427-34. doi: 10.1111/hae.12924. Epub 2016 Jun 13. Haemophilia. 2016. PMID: 27292088
Cited by
-
Update on clinical gene therapy for hemophilia.Blood. 2019 Jan 31;133(5):407-414. doi: 10.1182/blood-2018-07-820720. Epub 2018 Dec 17. Blood. 2019. PMID: 30559260 Free PMC article. Review.
-
Haemophilia A and haemophilia B: molecular insights.Mol Pathol. 2002 Feb;55(1):1-18. doi: 10.1136/mp.55.1.1. Mol Pathol. 2002. Corrected and republished in: Mol Pathol. 2002 Apr;55(2):127-44. doi: 10.1136/mp.55.2.127. PMID: 11836440 Free PMC article. Corrected and republished. Review.
-
Analysis of Bcl I and Xba I polymorphism in factor VIII gene to detect carriers of haemophilia a in Andhra Pradesh.Indian J Clin Biochem. 2002 Jan;17(1):94-8. doi: 10.1007/BF02867948. Indian J Clin Biochem. 2002. PMID: 23105343 Free PMC article.
-
Hemophilia Care in the Pediatric Age.J Clin Med. 2017 May 19;6(5):54. doi: 10.3390/jcm6050054. J Clin Med. 2017. PMID: 28534860 Free PMC article. Review.
-
Advances of adeno-associated virus applied in gene therapy to hemophilia from bench work to the clinical use.Blood Sci. 2019 Oct 21;1(2):130-136. doi: 10.1097/BS9.0000000000000030. eCollection 2019 Oct. Blood Sci. 2019. PMID: 35402808 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical